Toggle Main Menu Toggle Search

Open Access padlockePrints

Immune tolerance induction in severe haemophilia A: A UKHCDO inhibitor and paediatric working party consensus update

Lookup NU author(s): Dr Tina Biss, Dr Katherine Talks


Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


© 2021 John Wiley & Sons Ltd.Introduction: In good risk patients (historic inhibitor peak < 200BU), the International Immune Tolerance Study demonstrated equal efficacy to induce tolerance between high (200iu/kg/day) and low dose (50iu/kg ×3 times/week) immune tolerance induction (ITI) regimens. However, the trial stopped early on account of the excessive bleed rate in the low dose ITI arm. Methods: United Kingdom Haemophilia Centre Doctors’ Organization (UKHCDO) Paediatric and Inhibitor working parties considered available ITI data alongside the bi-phenotypic antibody emicizumab (Hemlibra®) efficacy and safety data to develop a consensus guideline for the future UK ITI guideline. Results: This revision of UKHCDO ITI guidance incorporates the recommendation to use emicizumab as a prophylaxis haemostatic agent to reduce bleeding rates and to facilitate low dose and reduced frequency of FVIII CFC for ITI in the majority of children. Conclusion: This consensus protocol will facilitate future evaluation of ITI outcomes in the evolving landscape of haemophilia therapeutics and ITI strategies.

Publication metadata

Author(s): Hart DP, Alamelu J, Bhatnagar N, Biss T, Collins PW, Hall G, Hay C, Liesner R, Makris M, Mathias M, Motwani J, Palmer B, Payne J, Percy C, Richards M, Riddell A, Talks K, Tunstall O, Chalmers E

Publication type: Article

Publication status: Published

Journal: Haemophilia

Year: 2021

Volume: 27

Issue: 6

Pages: 932-937

Print publication date: 01/11/2021

Online publication date: 17/08/2021

Acceptance date: 02/04/2020

ISSN (print): 1351-8216

ISSN (electronic): 1365-2516

Publisher: John Wiley and Sons Inc


DOI: 10.1111/hae.14381


Altmetrics provided by Altmetric